{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.1","upperLimit":"6.4","value":"3.7"},{"groupId":"OG001","lowerLimit":"1.8","upperLimit":"8.3","value":"5.3"},{"groupId":"OG002","lowerLimit":"1.8","upperLimit":"3.7","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Measure the timing of maintaining stable disease or partial response until disease progression assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest um diameters while on study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG000","title":"Cohort 1 - (Urothelial Progressive Disease)"},{"description":"Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG001","title":"Cohort 2 (Bone-only)"},{"description":"Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.","id":"OG002","title":"Cohort 3 (Rare Histologies)"}],"paramType":"MEDIAN","populationDescription":"42/50 were analyzed in cohort 1 because 5 participants withdrew, 2 were taken off study for adverse events and 1 was ineligible. In cohort 2, 5/6 patients were analyzed because 1 withdrew; and in cohort 3, 10/13 patients were analyzed because 1 withdrew and 2 were taken off study due to adverse events.","reportingStatus":"POSTED","timeFrame":"Median follow-up was 61.2 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}